Disclosure of safety information in foreign countries The GLP-1 receptor agonist used for this treatment has been approved for the indication of obesity by the FDA in the United States, the MFDS in South Korea, and the EMA in EU27 countries
575 ZhouH.YangJ.XinT.LiD.GuoJ.HuS.et al (2014)
You can message your provider anytime and share updates on your progress
Their monthly rate is higher than some competitors, but their long-term plans offer competitive pricing, especially the annual semaglutide plan at $149 per month
What does vary is state regulation and an individual practice's own credentialing policies, which shape what a given clinic actually offers
Both drugs : Share GLP-1 and glucagon receptor agonism, once-weekly subcutaneous dosing, similar GI side effect profiles, and investigational status